Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2015 07:00 ET | Source: Collegium Pharmaceutical

Collegium to Present at the 27th Annual Piper Jaffray Healthcare Conference

CANTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company's Chairman and CEO, will present at the 27th Annual...
November 12, 2015 06:00 ET | Source: Collegium Pharmaceutical

Collegium Reports Third Quarter Financial Results and Provides Corporate Update

CANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2015 and provided a corporate...
November 09, 2015 06:15 ET | Source: Collegium Pharmaceutical

Collegium to Host Conference Call to Discuss Q3 Financial Results and Provide Corporate Update

CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November...
November 09, 2015 06:00 ET | Source: Collegium Pharmaceutical

Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain

CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the United States Food and Drug Administration (FDA) has granted tentative approval to...
October 12, 2015 16:15 ET | Source: Collegium Pharmaceutical

Collegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain

CANTON, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be...
September 11, 2015 21:18 ET | Source: Collegium Pharmaceutical

Collegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER(TM), an Abuse-Deterrent Analgesic for Chronic Pain

CANTON, Mass., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and...
September 04, 2015 07:11 ET | Source: Collegium Pharmaceutical

Collegium to Present Highlights From Xtampza(TM) ER (Oxycodone Extended-Release Capsules) Clinical Development Program at PAINWeek

CANTON, Mass., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data from the clinical development program for Xtampza™ ER, an...
August 24, 2015 07:00 ET | Source: Collegium Pharmaceutical

Collegium Publishes Data From Xtampza(TM) ER Phase 3 Clinical Trial in the Journal PAIN

CANTON, Mass., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the Phase 3 clinical trial of Xtampza™ ER (oxycodone...
August 12, 2015 17:00 ET | Source: Collegium Pharmaceutical

Collegium Reports Second Quarter Financial Results and Provides Corporate Update

CANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the second quarter of 2015 and provided a corporate...
August 07, 2015 09:00 ET | Source: Collegium Pharmaceutical

Collegium to Host Conference Call to Discuss Financial Results and Provide Corporate Update

CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, August 13,...

Next Page keyboard_arrow_right